Key Points AbbVie generates billions in annual free cash flow and continues to expand its market share in immunology treatments. CRISPR Therapeutics is a leader in gene editing with a groundbreaking partnership to commercialize transformative medicines. Which healthcare stock is the better choice for your growth or income needs in the coming year? 10 stocks we like better than AbbVie › Choosing between a mature pharmaceutical giant and a speculative gene-editing pioneer requires a clear understanding of your personal risk tolerance. Do you prefer AbbVie (NYSE:ABBV) or CRISPR Therapeutics (NASDAQ:CRSP) in 2026? AbbVie is a diversified pharmaceutical company that provides stable cash flows through its established drug portfolio.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.